New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

42

More durable, broader spectrum boosters needed against COVID-19

Current COVID-19 booster shots have a problem: they last only about four months and appear to have limited efficacy in a vaccinated population. Clearly, a more durable, more efficacious vaccine is needed, but what should it be? The scientific community has not reached a consensus, according to BioSpace.

44

AstraZeneca, Sanofi’s positive RSV data shows 80% reduction in infants

AstraZeneca and Sanofi’s Phase III and Phase IIb clinical trials investigating the efficacy of nirsevimab, measured through the development of secondary infections, are impressing the pharma community with positive prespecified pooled analysis results. The data shows 79.5 percent efficacy in the prevention of lower respiratory tract infections, caused by infection of the respiratory syncytial virus (RSV).

46

Blow to Roche’s cancer immunotherapy prospects as 2nd trial fails

Development of a new cancer treatment pioneered by Roche was thrown into doubt on May 11 when the immunotherapy drug failed to slow progression of lung cancer in a second trial, hitting the Swiss pharmaceutical maker’s shares.

50

Cortexyme Charts New Course with Acquisition of Rare Disease Player

Cortexyme, a company focusing on treatments for degenerative diseases, entered into a deal to acquire Novosteo, which plays in the rare disease space. Once the deal is finalized, the merged companies will operate under the name Quince Therapeutics and trade under the ticker symbol QNCX.